ECM
BTAI icon

Endurant Capital Management’s BioXcel Therapeutics BTAI Stock Holding History

Endurant Capital Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3,569
Closed -$380K – 48
2023
Q2 		$380K Buy
+3,569
New +$1.19M 0.33% 32

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Endurant Capital Management's BTAI Position: Q2 2023 in Review

Endurant Capital Management sold out of BioXcel Therapeutics (BTAI) in Q2 2023, closing a stake of 728 shares — an estimated $242K sold.

Endurant Capital Management first reported a position in BTAI in Q1 2023 and held it in 1 quarter. The position peaked at $217K in Q1 2023. 88 funds tracked by Wall St. Rank hold BTAI as of Q2 2023.

  • Endurant Capital Management reported no remaining BioXcel Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Endurant Capital Management sold 728 BioXcel Therapeutics shares in Q2 2023, an estimated $242K.
  • Endurant Capital Management first reported a position in BioXcel Therapeutics in Q1 2023 and held it in 1 quarter.
  • Endurant Capital Management's BioXcel Therapeutics position peaked at $217K in Q1 2023.
  • 88 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2023.

Based on Endurant Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.